Vivos Therapeutics reported Q3 2024 revenue of $3.9 million, up 17% from Q3 2023, driven by increased product sales and higher service revenue. Gross margin improved to 60% from 53% year-over-year. The company achieved its ninth consecutive quarter of reduced operating expenses, with a 27% decrease in operating loss compared to Q3 2023.The company strengthened its market position with two significant developments: receiving FDA 510(k) clearance to treat moderate to severe OSA in children ages 6-17, and securing new AMA CPT medical codes for all Vivos CARE devices, effective January 2025. As of September 30, over 47,000 patients have been treated with Vivos' oral appliances, and more than 2,000 dentists have been trained in The Vivos Method.Following a $4.3 million equity offering in September, Vivos ended Q3 with $6.3 million in cash and $7.7 million in stockholders' equity. The company is expanding its new marketing and distribution model through medical sleep specialists and anticipates achieving positive cash flow from operations by mid-2025.

Vivos Therapeutics reported Q3 2024 revenue of $3.9 million, up 17% from Q3 2023, driven by increased product sales and higher service revenue. Gross margin improved to 60% from 53% year-over-year. The company achieved its ninth consecutive quarter of reduced operating expenses, with a 27% decrease in operating loss compared to Q3 2023.The company strengthened its market position with two significant developments: receiving FDA 510(k) clearance to treat moderate to severe OSA in children ages 6-17, and securing new AMA CPT medical codes for all Vivos CARE devices, effective January 2025. As of September 30, over 47,000 patients have been treated with Vivos' oral appliances, and more than 2,000 dentists have been trained in The Vivos Method.Following a $4.3 million equity offering in September, Vivos ended Q3 with $6.3 million in cash and $7.7 million in stockholders' equity. The company is expanding its new marketing and distribution model through medical sleep specialists and anticipates achieving positive cash flow from operations by mid-2025.